Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRK · Real-Time Price · USD
57.80
-1.46 (-2.46%)
Aug 28, 2026, 4:00 PM EDT - Market closed
Scholar Rock Holding Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
289
Market Cap
7.04B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 33.19M | 14.38M | 76.41% |
| Dec 31, 2021 | 18.82M | 3.41M | 22.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 989.61M |
| TG Therapeutics | 799.54M |
| Mirum Pharmaceuticals | 618.07M |
| Travere Therapeutics | 591.33M |
| Rhythm Pharmaceuticals | 239.92M |
| CG Oncology | 6.23M |
SRRK News
- 2 days ago - Scholar Rock to Present at Upcoming Investor Conferences - Business Wire
- 8 days ago - Scholar Rock price target raised to $64 from $58 at Wedbush - TheFly
- 8 days ago - Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission - Reuters
- 8 days ago - Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance - TheFly
- 8 days ago - Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan - Business Wire
- 13 days ago - Scholar Rock price target raised to $63 from $56 at JPMorgan - TheFly
- 13 days ago - Scholar Rock facioscapulohumeral muscular dystrophy treatment gets orphan status - TheFly
- 15 days ago - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire